Vericel Corp (VCEL) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
the bull case· 4
7
disclosed supplier and customer ties in SEC filings
sec filingsedgar317
managers reporting a position in thirteen F filings
13fJun 30 '2638
managers whose positions together make up four fifths of the reported value
13fJun 30 '26+2.03%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 4
11 of 25
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '267 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realized0.49%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '264
of the funds on file reporting a position in VCEL
n-portas of Jun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Vericel Corp moves with most closely, none share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
VCEL (Vericel Corp) has 4 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
tall tick = annual report · 1 on record
Vericel Corp
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
High 40.13 at 11:30 am ET, low 39.75 at 12:15 pm ET.
318 managers report a position worth $2.5B between them, and 38 of them hold 80% of it.